DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
The many ways to inhibit translation by Sorafenib in liver cancer cells
Sorafenib targets various tyrosine kinase receptors, inhibiting cell growth and proliferation, angiogenesis and metastasis in tumour cells. It is used to treat certain types of cancers including renal, thyroid and liver (hepatocellular carcinoma) cancers. Although Sorafenib is approved for advanced hepatocellular carcinoma, it only extends patient´s lives by a few months, highlighting the urgent need to better understand how it works and to develop more effective treatments. Sorafenib specifically inhibits translation initiation in hepatocellular carcinoma cells. Herein, we revealed that this inhibition results, at least, from the activation of PERK, triggering a stress response that leads to eIF2α phosphorylation, the inhibition of MNK1a-signalling-dependent eIF4E phosphorylation, and the aberrant assembly of the canonical eIF4F complex. Sorafenib also inhibits the ERK1/2 MAPK signalling in HepG2 cells. However, the mTORC1 pathway does appear to play a pivotal role in Sorafenib-dependent translation inhibition, as revealed by the phosphorylation levels of RPS6 and 4EBP1 proteins and the effects on translation of gene silencing 4EBP1/2 in Sorafenib-treated cells. Translation inhibition correlates with reduced production of cancer-promoting proteins like Cyclin D1 and c-Myc. Overexpression of the phosphomimetic eIF4E-S209D variant, which constitutively activates eIF4E, shows that inhibition of eIF4E phosphorylation directly causes Cyclin D1 down-regulation and cell-cycle delay in Sorafenib-treated cells. Taken together, our results confirm that Sorafenib induces translation reprogramming, whose understanding is crucial for improving its efficacy as a cancer therapy., Funding for open access publishing: Universidad de Sevilla/CBUA. This work was supported by the project R + D + i PID2022-136564NB-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and ERDF/UE "A way of making Europe" to J.d.l.C, who also acknowledges the Andalusian Platform of Biomodels and Resources in Genomic Edition, the FORTALECE Program (FORT 2023) from MCIN, and the Translacore (CA21154) and ProteoCure (CA20113) COST Actions from the EU (European Cooperation in Science and Technology) for support. This research was also funded by grant PRIN02020EK82R5 to S.B. J.M. is supported by the Instituto de Salud Carlos III, ISCIII (PI16/00090 and PI19/01266), and the Consejería de Salud y Familias (PI-0216–2020) of the Andalusian Government. We also thank the Biomedical Research Network Center for Liver and Digestive Diseases (CIBEREHD) funded by ISCIII and co-financed by ERDF "A way to achieve Europe). L.C. was a recipient of an FPU contract from the Spanish Ministry (FPU16/05127)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-136564NB-I00
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI16-00090
,
ISCIII PI19-01266
DOI: http://hdl.handle.net/10261/423197, https://api.elsevier.com/content/abstract/scopus_id/105016225392
HANDLE: http://hdl.handle.net/10261/423197, https://api.elsevier.com/content/abstract/scopus_id/105016225392